Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
- 1 May 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 35 (4), 359-366
- https://doi.org/10.1097/cji.0b013e31825481fe
Abstract
The effectivenes of cancer vaccines in inducing CD8+ T-cell responses remains a challenge, resulting in a need for testing more potent adjuvants. Our objective was to determine the safety and immunogenicity of vaccination against melanoma-related antigens employing MART-1, gp100, and tysosinase paptides combined with the TLR9 agonist PF-3512676 and local granulocyte macrophage-colony stimulating factor in oil emulsion. Using continuous monitoring of safety and a 2-stage design for immunologic efficacy, 20 immune response evaluable patients were targetted. Vaccinations were given subcutaneously on days 1 and 15 per cycle (1cycle=28 d) for up to 13 cycles. Interferon-γ enzyme-linked immunosorbent spot was used as the primary assay measuring the frequency of peripheral antigen-specific CD8+ T cells at days 50 and 90 compared with baseline (target≥9/20 immunologic responses). Clinical responses were measured by Response Evaluation Criteria In Solid Tumors every 8 weeks. Twenty-two (including 20 immune response evaluable) melanoma patients were enrolled. All had American Joint Committe on Cancer stage IV (5M1a, 6M1b, 11M1c) and most had previously received therapy. Eight had previously treated brain metastases. An average of 3.5 cycles of vaccination per patient was administered. Clinical response data were available for 21 patients. There were 2 partial response and 8 stable disease lasting 2–7 months. One patient with ongoing partial response continued on treatment. At a median follow-up of 7.39 months (range, 3.22–20.47 mo), median progression-free survival was 1.9 months (90% confidence interval, 1.84–3.68) and median overall survival was 13.4 months (90% confidence interval,11.3–∞). No regimen-related grade 3/4/5 toxicities were observed. There were 9/20 patients with positive enzyme-linked immunosorbent spot at day 50 and/or day 90. Our adjuvant regimen combining PF-3512676 and granulocyte macrophage-colony stimulating factor was safe and is worthy of further testing with these or alternative peptides, potentially in combination with antibodies that target immunoregulatory checkpoints.Keywords
This publication has 49 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- CTLA-4 blockade: therapeutic potential in cancer treatmentsOncoTargets and Therapy, 2010
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized TrialClinical Cancer Research, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696Clinical Cancer Research, 2009
- Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanomaJournal of Neurosurgery, 1998
- Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgeryAnnals of Neurology, 1993
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainThe New England Journal of Medicine, 1990
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsThe New England Journal of Medicine, 1988
- The current causes of death in patients with malignant melanomaEuropean Journal of Cancer (1965), 1978